Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 539-546 , July 2010

Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine

  • Sara Ahlgren

      Affiliations

    • Division of Nuclear Medicine, Department of Medical Sciences, Uppsala University, SE-751 85, Uppsala, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 18 471 3868; fax: +46 18 471 3432.
    • ,
  • Kristofer Andersson

      Affiliations

    • Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    • ,
  • Vladimir Tolmachev

      Affiliations

    • Division of Nuclear Medicine, Department of Medical Sciences, Uppsala University, SE-751 85, Uppsala, Sweden
    • Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden

Received 10 December 2009 ,Revised 7 February 2010 ,Accepted 23 February 2010.

References 

  1. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, et al. American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865–1878
  2. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gio M, et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281–293
  3. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–354
  4. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11(suppl 1):4–12
  5. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–5272
  6. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–3038
  7. Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer. 1994;70:335–341
  8. Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv. 2006;3:53–70
  9. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14:2999–3019
  10. Tolmachev V, Orlova A. Update on Affibody molecules for in vivo imaging of targets for cancer therapy. Minerva Biotecnol. 2009;21:21–30
  11. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res. 2006;66:4339–4348
  12. Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem. 2008;19:235–243
  13. Wållberg H, Ahlgren S, Widström C, Orlova A. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol. 2010;12:54–62
  14. Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, et al. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant Affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med. 2009;50:781–789
  15. Tran T, Engfeldt T, Orlova A, Widström C, Bruskin A, Tolmachev V, et al. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem. 2007;18:549–558
  16. Kowalsky RJ, Dalton DR. Technical problems associated with the production of technetium Tc 99m tin(II) pyrophosphate kits. Am J Hosp Pharm. 1981;38:1722–1726
  17. Guggenberg EV, Mikolajczak R, Janota B, Riccabona G, Decristoforo C. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. J Pharm Sci. 2004;93:2497–2506
  18. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandström M, et al. Synthetic Affibody molecules: A novel class of affinity ligands for molecular imaging of HER2 expressing malignant tumors. Cancer Res. 2007;67:2178–2189
  19. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201–212

PII: S0969-8051(10)00034-X

doi: 10.1016/j.nucmedbio.2010.02.009

Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 539-546 , July 2010

Article Tools

* Image Usage & Resolution